SEATTLE--(BUSINESS WIRE)--Northstar Neuroscience, Inc. (NASDAQ: NSTR), a medical device company developing therapies for the treatment of neurological diseases and disorders, announced today that the last patient in the Company’s EVEREST pivotal trial(a) for stroke motor recovery completed four week follow-up, the primary endpoint for the trial.
